Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects-Reference-Cited by-同舟云学术

Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects

Published:2018-09-28 Issue:12 Volume:84 Page:2790-2801
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Nakov Roumen¹,Gattu Sreekanth¹,Wang Jessie²,Velinova Maria³,Schaffar Gregor¹,Skerjanec Andrej⁴

Affiliation:

1. Hexal AG; Holzkirchen Germany

2. Sandoz Inc.; Princeton NJ USA

3. PRA Health Sciences; Groningen Netherlands

4. Sandoz AG; Basel Switzerland

Funder

Fiona Goodwin of Spirit Medical Communications Ltd

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13731/fullpdf

Reference42 articles.

1. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice;Weycker;Support Care Cancer,2016

2. Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update;Smith;J Clin Oncol,2015

3. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations;Aapro;Support Care Cancer,2017

4. A systematic literature review of overall survival and delivered dose intensity in cancer patients receiving chemotherapy and G-CSF in randomized control trials;Lyman;Blood,2017

5. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials;Wang;Support Care Cancer,2015

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. INVESTIGATING THE PHYSICOCHEMICAL, NON-CLINICAL, AND CLINICAL CRITERIA FOR ASSESSING COMPARABILITY IN RANIBIZUMAB BIOSIMILARS: A COMPREHENSIVE REVIEW;FARMACIA;2024

2. Achieving white blood cell equity: are the safety profiles of biosimilar and reference pegfilgrastims comparable?;Future Oncology;2023-08-23

3. A multicenter phase II trial of primary prophylactic PEG‐rhG‐CSF in pediatric patients with solid tumors and non‐Hodgkin lymphoma after chemotherapy: An interim analysis;Cancer Medicine;2023-05-15

4. Cost-effectiveness analysis of pegfilgrastim in patients with non-small cell lung cancer receiving ramucirumab plus docetaxel in Japan;Supportive Care in Cancer;2022-05-07

5. A review of the totality of evidence supporting the development and approval of a pegfilgrastim biosimilar (LA-EP2006);Current Medical Research and Opinion;2022-04-17